Simulations Plus(US:SLP) Prnewswireยท2025-07-31 02:06Group 1 - The core issue involves potential violations of federal securities laws by Simulations Plus, Inc. due to allegations of providing misleading business information to investors [1] - Simulations Plus reported third fiscal quarter sales of $20.4 million, missing the consensus estimate by approximately $500,000, and experienced a net loss of $67.3 million compared to a net income of $3.1 million in the same period of 2024 [3] - Following the negative financial report, Simulations Plus's stock price dropped by $4.70 per share, or 25.76%, closing at $12.97 per share on July 15, 2025 [3] Group 2 - Simulations Plus is a life sciences software and consulting company that provides advanced biosimulation tools and consulting services to pharmaceutical and biotechnology companies globally [2] - The company has implemented workforce reductions and cost-cutting measures as part of an operational restructuring plan initiated in June 2025 [3]